Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumabExclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and...
Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumabExclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and...
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel...
Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin...
• Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition...
Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS Approximately 50%...
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first...
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim...
Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt...
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero...
- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022...
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles...
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at...
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a...
Physician-led network offering complimentary skin cancer screenings across its network of clinics throughout OctoberMAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE)...
– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) –– Company...
STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to dateOver 8,000 migraine attacks treated with more...